_____________________
Presentation
The “Biotherapies – Biotherapies by nucleic acid vectorization” team is developing 3 main lines of research:
* Development of innovative strategies for RNA delivery, small interfering RNAs or mRNAs.
* Pharmacological evaluation of new therapeutic strategies, mainly in the fields of inflammatory diseases, hepatic fibrosis and cancer. fibrosis or cancer.
* Development of tumor-penetrating and tumor-interfering peptides (TP and IP), capable of specifically penetrating tumor cells, without any effect on healthy cells, and blocking the interaction between two proteins deregulated during tumor transformation.
CNRS honors Néovacs and UTCBS, united for a therapeutic RNA vaccine against asthma
Suresnes, August 29, 2024 - 8am CET - Neovacs (Euronext Growth Paris : ALNEV), a preclinical-stage biopharmaceutical company developing novel therapies for inflammatory and autoimmune diseases, is honored to be listed among the latest CNRS publications following the...
Publication in Advanced Science of Preclinical tests obtained with a pFAR plasmid
Gene Electrotransfer via Conductivity-Clamped Electric Field Focusing Pivots Sensori-Motor DNA Therapeutics: “A Spoonful of Sugar Helps the Medicine Go Down” https://doi.org/10.1002/advs.202401392
Khair Alareth, Caroline Roques and Nasir Arafath with Nathalie Mignet to present UTCBS’s work at the Controlled release society international congress in Bologna.
UTCBS presents its work at the international congress of the "controlled release society" in Bologna. The UTCBS team has shown the interest of nanoparticles both for the imaging of ROS in vivo and the promotion of antioxydant therapeutic activity. Caroline Roques...
The Alnylam Pharmaceuticals 2024 “Interfering RNA & Rare Diseases” Prize has been awarded to Virginie Escriou,
The Alnylam Pharmaceuticals 2024 “Interfering RNA & Rare Diseases” Prize has been awarded to Virginie Escriou,